Intravitreal bevacizumab for the treatment of myopic choroidal neovascularisation in an Asian population.

Dear Editor, Myopic choroidal neovascularisation (mCNV) is one of the most common causes of permanent central visual loss in patients with high myopia,1 and its natural history results in the development of chorioretinal atrophy around the regressed mCNV, causing further progressive central visual loss.2 Therefore there is a need to fi nd treatment options which will not only regress the mCNV but also preserve the neurosensory elements within the macula. Studies using “off-label” intravitreal bevacizumab (Avastin) have shown promising short-term visual outcomes.3,4 Our study aimed to determine the effi cacy and safety of intravitreal bevacizumab for the treatment of mCNV in our Asian population. This was a prospective, interventional case series which was approved by the Institution Review Board of the Singapore National Eye Centre, using intravitreal bevacizumab (1.25 mg/0.05 mL). Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT), and fundus fl uorescein angiography (FA) preand posttreatment, and the number of treatments required were studied. Changes in the BCVA and CRT were analysed using the Wilcoxan signed rank test. Variables affecting visual outcomes including prior photodynamic therapy (PDT) and the number of bevacizumab injections were Intravitreal Bevacizumab for the Treatment of Myopic Choroidal Neovascularisation in an Asian Population